Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials.

Hiddo J Lambers Heerspink Priya VartNiels JongsBrendon L NeuenGeorge BakrisBrian ClaggettMuthiah VaduganathanFinnian McCauslandKieran F DochertyPardeep S JhundScott D SolomonVlado PerkovicJohn Joseph Valentine McMurray

Published in: Diabetes, obesity & metabolism (2023)

Combined disease-modifying treatment with an SGLT2 inhibitor and MRA in patients with type 2 diabetes and CKD may substantially increase the number of years free from kidney failure and mortality.

Keyphrases

chronic kidney disease
clinical trial
end stage renal disease
double blind
open label
phase ii
phase iii
cardiovascular events
placebo controlled
risk factors
magnetic resonance imaging
contrast enhanced
type diabetes
study protocol
replacement therapy